Full-Time

Platform Owner Database

Digital

Deadline 8/27/26
Sanofi

Sanofi

10,001+ employees

Global pharma company; vaccines and R&D

No salary listed

Barcelona, Spain

Hybrid

Hybrid work is indicated for the Barcelona hub.

Bachelor's

Category
Engineering Management (1)
Required Skills
Bash
Microsoft Azure
Agile
Python
MySQL
GitHub Actions
R
Git
ServiceNow
SQL
Postgres
RDBMS
Tableau
AWS
JIRA
Terraform
Ansible
SCRUM
Confluence
Splunk
Oracle
Snowflake

Get referred to Sanofi

See people who can refer or advise you

Requirements
  • 10-15 years of experience managing a Data Engineering team and working with cross-functional teams.
  • Good understanding of agile and Scrum development processes and concepts.
  • Ability to work in a fast-paced, constantly evolving environment and manage multiple priorities.
  • Ability to solve complex issues pragmatically and provide service-oriented support.
  • Ability to work flexibly and collaboratively with attention to detail and technical intuition.
  • Excellent written, verbal, and interpersonal communication skills for executive-level communication and collaboration.
  • Proven experience partnering with application teams and translating technical concepts for non-technical stakeholders.
  • Experience with AWS and Azure cloud services.
  • Good knowledge of SQL and relational database technologies and concepts.
  • Experience working with data models and query tuning.
  • Experience with data warehousing solutions.
  • Experience with Integration Services, including IICS.
  • Working knowledge of scripting languages, including Python.
  • Familiarity with source code management tools.
  • Experience with project management tools such as JIRA and Confluence.
  • Familiarity with service management tools.
  • A bachelor's degree in computer science, engineering, or equivalent.
Responsibilities
  • Lead the architecture, technical design, administration, security, and evolution of database services while staying current with company standards, industry practices, and emerging technologies.
  • Design and develop optimized modules that meet reliability, reusability, latency, performance, and running-cost requirements.
  • Develop, industrialize, and support database platforms in a regulated environment, including deployment of cloud databases, hosting platforms, storage, and migration services such as AWS SCT and DMS.
  • Work with PostgreSQL, MySQL, Microsoft SQL, and Oracle, including engineered systems.
  • Support Data module engineers in designing optimized data models, database platforms, and services.
  • Drive automation using GitLab, GitHub Actions, Terraform, and Ansible, with Python, JSON, YAML, and shell scripting.
  • Use backup systems such as NetBackup and Commvault and monitoring tools such as Splunk and BPPM to maintain operational visibility and reliability.
  • Ensure database platforms and services comply with GxP and other applicable regulatory requirements.
  • Provide Level 3 operational support and work transversely with Cloud and Data architects, Product Owners, Scrum Masters, development teams, and external partners.
  • Lead and manage a team of Data Engineering Experts, set team direction, and foster a collaborative, high-performing environment.
  • Support team members' personal and professional development through mentoring, technology evangelism, and advocacy.
  • Partner with business teams to understand requirements, translate them into technical needs, and support operational excellence.
Desired Qualifications
  • Working in the life sciences or pharmaceutical industry is a plus.
  • Experience with compliance and cybersecurity requirements is a plus.
  • Experience with GCP cloud services is a plus.
  • Experience with Snowflake is a plus.
  • Experience with Tibco is a plus.
  • Knowledge of R is a plus.
  • Familiarity with GitHub is a plus.
  • Familiarity with PowerBI and Tableau is a plus.
  • Familiarity with ServiceNow is a plus.
  • Cloud certifications in AWS, Azure, Snowflake, or IICS are a plus.

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 sales rose 17.8%; Dupixent topped €5.2 billion for the quarter.
  • July 30 upgraded 2026 guidance to around 10% sales growth, with higher EPS.
  • August 4 MenQuadfi infant approval widens vaccine reach; Nexviazyme's June phase 3 readout strengthens pipeline.

What critics are saying

  • Dupixent faces tougher H2 2026 comparisons, threatening growth after the €5.2 billion quarter.
  • Cenrifki carries liver injury risk; strict monitoring can slow adoption and invite liability.
  • Dupixent concentration and Regeneron's November 2024 lawsuit threaten Sanofi's core growth engine.

What makes Sanofi unique

  • Dupixent and partnered launch engine generate repeatable immunology cash flows across geographies.
  • Sanofi converted 2026 approvals for Sarclisa Escena, Wayrilz, and Cenrifki into launches.
  • Paulo Fontoura's September 1 R&D mandate centralizes translational science and regulatory execution.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Business Wire
Aug 13th, 2026
Epicrispr Biotechnologies Closes $90 Million Oversubscribed Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Epicrispr Biotechnologies Closes $90 Million Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Morningstar
Aug 12th, 2026
InduPro raises $77M Series B, doses first patient in Phase 1 trial of bispecific ADC for lung cancer

InduPro has closed a $77 million Series B financing round and dosed its first patient in a Phase 1 study of IDP-001, its lead oncology programme. The biotechnology company is developing IDP-001, a bispecific antibody-drug conjugate targeting EGFR and a novel tumour-associated proximity antigen, for treating advanced squamous non-small cell lung cancer and other solid tumours. The Column Group led the financing round, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective, Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company. Proceeds will support Phase 1 clinical development and early proof-of-concept data generation for IDP-001, whilst advancing InduPro's broader preclinical pipeline. InduPro uses a proximity-guided platform to map protein spatial relationships on cell surfaces for discovering selective co-target pairs.

FinancialContent
Jul 24th, 2026
Scribe Therapeutics prices upsized $129M IPO at top of range

Scribe Therapeutics, a clinical-stage biotechnology company developing in vivo CRISPR technologies, has priced its upsized initial public offering at $15.00 per share, the high end of its range. The company is offering 8,580,000 shares, expecting to raise $128.7 million in gross proceeds before fees and expenses. Scribe has also granted underwriters a 30-day option to purchase up to 1,287,000 additional shares. The shares are expected to begin trading on the Nasdaq Global Market on 24 July 2026 under the ticker symbol "SCTX", with the offering closing on 27 July 2026. Additionally, Scribe has agreed to sell 500,000 shares at the same price to Sanofi in a concurrent private placement. Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo Securities are serving as joint book-running managers.

Associated Press
Jul 10th, 2026
Sanofi's Sarclisa Escena approved in US as first anticancer drug delivered via on-body injector

The US Food and Drug Administration has approved Sanofi's subcutaneous Sarclisa Escena for treating multiple myeloma, making it the first anticancer treatment administered through an on-body injector. The therapy uses Enable Injections' CirCLIQ device, which delivers the drug automatically with a retractable 30g needle. The approval was supported by the IRAKLIA phase 3 study, which demonstrated that Sarclisa Escena delivered via the on-body injector provided similar efficacy and safety compared to intravenous infusion, with significantly shorter treatment time and fewer infusion-related reactions. The study showed a 71.1% objective response rate in patients with relapsed or refractory multiple myeloma. More than 70,000 patients worldwide have been treated with Sarclisa-based regimens. The on-body injector aims to reduce physical burden on healthcare providers whilst offering patients greater convenience during treatment.

Yahoo Finance
Jul 5th, 2026
Sanofi appoints Paulo Fontoura as R&D chief to accelerate pharma pipeline transformation

Sanofi has appointed Paulo Fontoura as Executive Vice President and Global Head of Research & Development Pharma, effective 1 September. Based in Paris, Fontoura will oversee the company's innovation engine, spanning research, translational medicine, clinical development, and regulatory affairs. He succeeds Dr Houman Ashrafian, who is leaving to pursue new opportunities. Fontoura brings over 25 years of experience across academic medicine, translational science, and pharmaceutical innovation. The appointment comes as Sanofi drives an R&D transformation whilst progressing its pipeline across multiple therapeutic areas. Separately, MacroGenics confirmed it will receive $24.5 million in regulatory milestone payments from Sanofi following FDA accelerated approval of TZIELD to delay decline in endogenous insulin production in children. Sanofi is a global biopharmaceutical company focusing on immunology, rare diseases, and oncology.